In today’s ACT Brief, we examine how large de-identified datasets are reshaping trial design and site strategy, why global ...

Understand where real-world evidence most effectively complements or substitutes traditional trial data, from post-market surveillance and label expansion to challenging areas such as rare disease ...

Explore how large-scale, de-identified real-world datasets enable more representative trial design, improve site selection, ...

In today’s ACT Brief, we look at how FDA policy is accelerating the use of de-identified real-world evidence in clinical ...

In today’s ACT Brief, we examine why life sciences companies are maintaining DEI commitments amid political pressure, what’s ...

In today’s ACT Brief, we look at why durable signal closure is emerging as a defining metric in risk-based quality management ...

In today’s ACT Brief, we look at how global clinical development is evolving through decentralized models and emerging ...

Meeting sites where they are—within their systems, workflows, and technology—is something we’re deeply interested in ...

A look at how efficiency, access, platformization, AI, non-traditional players, and regulatory recovery are expected to reshape clinical operations in 2026. Efficiency, redefined: Faster trials ...

This latest government action impacting the research space would allocate $116.8 billion in 2026 funding to the HHS—an increase of $210 million from 2025. Within the HHS, the National Institutes of ...

Traditional clinical trial data are pseudonymized data, and these data may not contain information on a patient that directly identifies them, like a name, address, or phone number. However, ...

The clinical trials landscape will continue evolving toward greater decentralization, enhance patient-centricity, and increased global diversification. Industry projections suggest that by 2025, ...